Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use

被引:207
|
作者
Baggish, Aaron L. [1 ,2 ]
Weiner, Rory B. [1 ,2 ]
Kanayama, Gen [3 ,4 ,5 ]
Hudson, James I. [3 ,4 ,5 ]
Lu, Michael T. [6 ,7 ]
Hoffmann, Udo [6 ,7 ]
Pope, Harrison G., Jr. [3 ,4 ,5 ]
机构
[1] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Performance Program, Boston, MA 02114 USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
[3] McLean Hosp, Biol Psychiat Lab, 115 Mill St, Belmont, MA 02178 USA
[4] McLean Hosp, Psychiat Epidemiol Res Program, 115 Mill St, Belmont, MA 02178 USA
[5] Harvard Med Sch, Dept Psychiat, Boston, MA USA
[6] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA
[7] Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA
关键词
anabolic-androgenic steroids; atherosclerosis; cardiology; cardiomyopathy; diastolic dysfunction; men; RISK-FACTORS; VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION; TISSUE DOPPLER; SOCIETY; WEIGHTLIFTERS; TESTOSTERONE; CONSEQUENCES; DYSFUNCTION; PREVALENCE;
D O I
10.1161/CIRCULATIONAHA.116.026945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remain incompletely understood. METHODS: Using a cross-sectional cohort design, we recruited 140 experienced male weightlifters 34 to 54 years of age, comprising 86 men reporting >= 2 years of cumulative lifetime AAS use and 54 nonusing men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction), LV diastolic function (early relaxation velocity), and coronary atherosclerosis (coronary artery plaque volume). RESULTS: Compared with nonusers, AAS users demonstrated relatively reduced LV systolic function (mean +/- SD left ventricular ejection fraction = 52 +/- 11% versus 63 +/- 8%; P < 0.001) and diastolic function (early relaxation velocity = 9.3 +/- 2.4 cm/second versus 11.1 +/- 2.0 cm/second; P < 0.001). Users currently taking AAS at the time of evaluation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49 +/- 10% versus 58 +/- 10%; P < 0.001) and diastolic function (early relaxation velocity = 8.9 +/- 2.4 cm/second versus 10.1 +/- 2.4 cm/second; P=0.035) compared with users currently off-drug (N=28). In addition, AAS users demonstrated higher coronary artery plaque volume than nonusers (median [interquartile range] 3 [0, 174] mL(3) versus 0 [0, 69] mL(3);P=0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10-year increase in cumulative duration of AAS use: 0.60 SD units [0.16-1.03 SD units]; P=0.008). CONCLUSIONS: Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS-associated adverse cardiovascular phenotypes may represent a previously underrecognized public-health problem.
引用
收藏
页码:1991 / +
页数:26
相关论文
共 50 条
  • [41] Anabolic-androgenic steroid use: Patterns of use among a national sample of Canadian adolescents and young adults
    Ganson, Kyle T.
    Hallward, Laura
    Cunningham, Mitchell L.
    Murray, Stuart B.
    Nagata, Jason M.
    PERFORMANCE ENHANCEMENT & HEALTH, 2023, 11 (01)
  • [42] Cardiovascular Disease in Anabolic Androgenic Steroid Users
    Windfeld-Mathiasen, Josefine
    Heerfordt, Ida M.
    Dalhoff, Kim Peder
    Andersen, Jon Traerup
    Andersen, Michael Asger
    Johansson, Karl Sebastian
    Biering-Sorensen, Tor
    Olsen, Flemming Javier
    Horwitz, Henrik
    CIRCULATION, 2025, 151 (12) : 828 - 834
  • [43] Anabolic-androgenic steroid use among women-A qualitative study on experiences of masculinizing, gonadal and sexual effects
    Havnes, Ingrid Amalia
    Jorstad, Marie Lindvik
    Innerdal, Ingveig
    Bjornebekk, Astrid
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 95
  • [44] Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?
    Kaufman, Marc J.
    Kanayama, Gen
    Hudson, James I.
    Pope, Harrison G., Jr.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2019, 100 : 180 - 207
  • [45] Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use
    McBride, J. Abram
    Coward, Robert M.
    ASIAN JOURNAL OF ANDROLOGY, 2016, 18 (03) : 373 - 380
  • [46] Brain connectivity aberrations in anabolic-androgenic steroid users
    Westlye, Lars T.
    Kaufmann, Tobias
    Alnaes, Dag
    Hullstein, Ingunn R.
    Bjornebekk, Astrid
    NEUROIMAGE-CLINICAL, 2017, 13 : 62 - 69
  • [47] Multisubstance Use as a Feature of Addiction to Anabolic-Androgenic Steroids
    Skarberg, Kurt
    Nyberg, Fred
    Engstrom, Ingemar
    EUROPEAN ADDICTION RESEARCH, 2009, 15 (02) : 99 - 106
  • [48] Association Between Narcotic Use and Anabolic-Androgenic Steroid Use Among American Adolescents
    Denham, Bryan E.
    SUBSTANCE USE & MISUSE, 2009, 44 (14) : 2043 - 2061
  • [49] Is There an Association between the Use of Anabolic-Androgenic Steroids and Criminality?
    Skarberg, Kurt
    Nyberg, Fred
    Engstrom, Ingemar
    EUROPEAN ADDICTION RESEARCH, 2010, 16 (04) : 213 - 219
  • [50] Random forest model to identify factors associated with anabolic-androgenic steroid use
    Manoochehri, Zohreh
    Barati, Majid
    Faradmal, Javad
    Manoochehri, Sara
    BMC SPORTS SCIENCE MEDICINE AND REHABILITATION, 2021, 13 (01)